Kuwahara Motoi, Kusunoki Susumu
Department of Neurology, Kindai University Faculty of Medicine.
Brain Nerve. 2016 Dec;68(12):1423-1429. doi: 10.11477/mf.1416200612.
The efficacy of plasma exchange (PE) and intravenous immunoglobulin (IVIg) therapies for Guillain-Barré syndrome have been established by numerous randomized controlled trials. However, 10-20 % of GBS patients cannot walk without aid after one year from onset of the disease. Thus, new treatment is required for these intractable cases. The Japan GBS outcome study (J-GOS) has been conducted to identify clinical or biological markers that predict the prognosis of Japanese GBS patients at an early stage. In the future, we expect to provide intractable patients so predicted with novel therapy, including molecular target drugs.
血浆置换（PE）和静脉注射免疫球蛋白（IVIg）治疗吉兰-巴雷综合征的疗效已通过大量随机对照试验得到证实。然而，10%-20%的吉兰-巴雷综合征患者在发病一年后仍需借助外力才能行走。因此，这些难治性病例需要新的治疗方法。日本吉兰-巴雷综合征预后研究（J-GOS）已经开展，以确定能够在早期预测日本吉兰-巴雷综合征患者预后的临床或生物学标志物。未来，我们期望为这些预测出的难治性患者提供包括分子靶向药物在内的新型治疗方法。
